New insights into airway remodelling in asthma and its possible modulation

Current Opinion in Allergy and Clinical Immunology

Volumn 8, Issue 5, 2008, Pages 367-375

  Folli, Chiara ^a   Descalzi, Desideria ^a   Scordamaglia, Francesca ^a   Riccio, Anna Maria ^a   Gamalero, Cinzia ^a   Canonica, Giorgio Walter ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

Airway epithelium; Airway remodelling; Asthma; Asthma therapy; Fibroblasts; Inflammation

Indexed keywords

BECLOMETASONE DIPROPIONATE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CD40 ANTIGEN; CORTICOSTEROID; FORMOTEROL; HERMES ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1 ANTIBODY; INTERLEUKIN 13; INTERLEUKIN 4; INTERLEUKIN 6; SALBUTAMOL; THY 1 ANTIGEN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1;

AIRWAY; ANTIINFLAMMATORY ACTIVITY; ASTHMA; BRONCHIOLE; BRONCHUS; FIBROBLAST; HUMAN; IMMUNOMODULATION; INFLAMMATION; MESENCHYME; NONHUMAN; PRIORITY JOURNAL; RESPIRATORY EPITHELIUM; REVIEW; TISSUE REPAIR; TRACHEA;

ANTI-INFLAMMATORY AGENTS; ASTHMA; EPITHELIUM; FIBROBLASTS; HUMANS; INFLAMMATION; LUNG;

EID: 53549096218     PISSN: 15284050     EISSN: 14736322     Source Type: Journal    
DOI: 10.1097/ACI.0b013e32830a7086     Document Type: Review

References (82)

1. Hackett TL, Knight DA. The role of epithelial injury and repair in the origins of asthma. Curr Opin Allergy Clin Immunol 2007; 7:63-68.
2. Kunzmann S, Schmidt-Weber C, Zingg JM, et al. Connective tissue growth factor expression is regulated by histamine in lung fibroblasts: potential role of histamine in airway remodeling. J Allergy Clin Immunol 2007; 119:1398-1407.
3. Lundback B, Dahl R. Assessment of asthma control and its impact on optimal treatment strategy. Allergy 2007; 62:611-619.
4. Renauld JC. New insights into the role of cytokines in asthma. J Clin Pathol 2001; 54:577-589.
5. Wenzel SE. Asthma: defining of the persistent adult phenotypes. Lancet 2006; 368:804-813.
6. Saglani S, Wilson N, Bush A. Should preschool wheezers ever be treated with inhaled corticosteroids? Semin Respir Crit Care Med 2007; 28:272-285.
7. Saglani S, Malmström K, Pelkonen AS, et al. Airway remodeling and inflammation in symptomatic infants with reversible airflow obstruction. Am J Respir Crit Care Med 2005; 171:722-727.
8. Tang ML, Wilson JW, Stewart AG, Royce SG. Airway remodelling in asthma: current understanding and implications for future therapies. Pharmacol Ther 2006; 112:474-488.
9. Romagnani S. The increased prevalence of allergy and the hygiene hypothesis: missing immune deviation, reduced immune suppression, or both? Immunology 2004; 112:352-363.
10. Romagnani S. Coming back to a missing immune deviation as the main explanatory mechanism for the hygiene hypothesis. J Allergy Clin Immunol 2007; 119:1511-1513.
11. Bisgaard H, Hermansen MN, Buchvald F, et al. Childhood asthma after bacterial colonization of the airway in neonates. N Engl J Med 2007; 357:1487-1495.
12. Wills-Karp M. Immunologic basis of antigen-induced airway hyperresponsiveness. Annu Rev Immunol 1999; 17:255-281.
13. Moser R, Fehr J, Bruijnzeel PL. IL-4 controls the selective endothelium-driven transmigration of eosinophils from allergic individuals. J Immunol 1992; 149:1432-1438.
14. Grunig G, Warnock M, Wakil AE, et al. Requirement for IL-13 independently of IL-4 in experimental asthma. Science 1998; 282:2261-2263.
15. Zhu Z, Homer RJ, Wang Z, et al. Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production. J Clin Invest 1999; 103:779-788.
16. Wen FQ, Liu XD, Terasaki Y, et al. Interfefon-gamma reduces interleukin-4- and interleukin-13-augmented transforming growth factor-beta2 production in human bronchial epithelial cells by targeting Smads. Chest 2003; 123:372S-373S.
17. Redington AE, Madden J, Frew AJ, et al. Transforming growth factor-beta 1 in asthma. Measurement in bronchoalveolar lavage fluid. Am J Respir Crit Care Med 1997; 156:642-647.
18. Morishima Y, Nomura A, Uchida Y, et al. Triggering the induction of myofibroblast and fibrogenesis by airway epithelial shedding. Am J Respir Cell Mol Biol 2001; 24:1-11.
19. Terada N, Hamano N, Nomura T, et al. Interleukin-13 and tumour necrosis factor-alpha synergistically induce eotaxin production in human nasal fibroblasts. Clin Exp Allergy 2000; 30:348-355.
20. Miyamasu M, Yamaguchi M, Nakajima T, et al. Th1-derived cytokine IFN-gamma is a potent inhibitor of eotaxin synthesis in vitro. Int Immunol 1999; 11:1001-1004.
21. Hall MC, Young DA, Waters JG, et al. Thecomparative role of activator protein 1 and Smad factors in the regulation of Timp-1 and MMP-1 gene expression by transforming growth factor-beta 1. J Bid Chem 2003; 278:10304-10313.
22. Corrigan CJ. Eotaxin and asthma: some answers, more questions. Clin Exp Immunol 1999; 116:1-3.
23. Lukacs NW, Oliveira SH, Hogaboam CM. Chemokines and asthma: redundancy of function or a coordinated effort? J Clin Invest 1999; 104:995-999.
24. Gonzalo JA, Lloyd CM, Wen D, et al. The coordinated action of CC chemokines in the lung orchestrates allergic inflammation and airway hyperresponsiveness. J Exp Med 1998; 188:157-167.
25. Umetsu DT, Dekruyff RH. Immune dysregulation in asthma. Curr Opin Immunol 2006; 18:727-732.
26. Akdis M, Verhagen J, Taylor A, et al. Immune responses in healthy and allergic individuals are characterized by a fine balance between allergen-specific T regulatory 1 and T helper 2 cells. J Exp Med 2004; 199:1567-1575.
27. Akbari O, Stock P, Meyer E, et al. Essential role of NKT cells producing IL-4 and IL-13 in the development of allergen-induced airway hyperreactivity. Nat Med 2003; 9:582-588.
28. Vijayanand P, Seumois G, Pickard C, et al. Invariant natural killer T cells in asthma and chronic obstructive pulmonary disease. N Engl J Med 2007; 356:1410-1422.
29. Ferlazzo G. Natural killer and dendritic cell liaison: recent insights and open questions. Immunol Lett 2005; 101:12-17.
30. Scordamaglia F, Balsamo M, Scordamaglia A, et al. Perturbations of NK cell regulatory functions in respiratory allergic diseases. J Allergy Clin Immunol 2008; 121:479-485.
31. Bergeron C, Boulet LP. Structural changes in airway diseases: characteristics, mechanisms, consequences, and pharmacologic modulation. Chest 2006; 129:1068-1087.
32. Jeffery PK. Remodeling and inflammation of bronchi in asthma and chronic obstructive pulmonary disease. Proc Am Thorac Soc 2004; 1:176-183.
33. Pascual RM, Peters SP. Airway remodeling contributes to the progressive loss of lung function in asthma: an overview. J Allergy Clin Immunol 2005; 116:477-486.
34. Holgate ST, Holloway J, Wilson S, et al. Understanding the pathophysiology of severe asthma to generate new therapeutic opportunities. J Allergy Clin Immunol 2006; 117:496-506.
35. Holgate ST, Polosa R. The mechanisms, diagnosis, and management of severe asthma in adults. Lancet 2006; 368:780-793.
36. Holgate ST. Epithelium dysfunction in asthma. J Allergy Clin Immunol 2007; 120:1233-1244. This review evidences the role played by airway epithelium in the orchestration of the inflammatory response in asthma.
37. Takizawa H. Novel strategies for the treatment of asthma. Recent Patents on Inflamm Allergy Drug Discov 2007; 1:13-19.
38. Knight DA, Stewart GA, Lai ML, Thompson PJ. Epithelium-derived inhibitory prostaglandins modulate human bronchial smooth muscle responses to histamine. Eur J Pharmacol 1995; 272:1-11.
39. Watkins DN, Gariepp MJ, Thompson PJ. Regulation of the inducible cyclooxygenase pathway in human cultured airway epithelial (A549) cells by nitric oxide. Br J Pharmacol 1997; 121:1482-1488.
40. Watkins DN, Peroni DJ, Basclain KA, et al. Expression and activity of nitric oxide synthases in human airway epithelium. Am J Respir Cell Mol Biol 1997; 16:629-639.
41. Davies DE, Wicks J, Powell RM, et al. Airway remodeling in asthma: new insights. J Allergy Clin Immunol 2003; 111:215-225.
42. Holgate ST. Epithelial damage and response. Clin Exp Allergy 2000; 30 (S1):37-41.
43. Cagnoni F, Oddera S, Giron-Michel J, et al. CD40 on adult human airway epithelial cells: expression and proinflammatory effects. J Immunol 2004; 172:3205-3214.
44. Olsson S, Cagnoni F, Dignetti P, et al. Low concentrations of cytokines produced by allergen-stimulated peripheral blood mononuclear cells have potent effects on nasal polyp-derived fibroblasts. Clin Exp Immunol 2003; 132:254-260.
45. Laberge S, El Bassam S. Cytokines, structural cells of the lungs and airway inflammation. Paediatr Respir Rev 2004; 5 (SA):S41-S45.
46. Schmidt M, Sun G, Stacey MA, et al. Identification of circulating fibrocytes as precursors of bronchial myofibroblasts in asthma. J Immunol 2003; 171:380-389.
47. Gizycki MJ, Adelroth E, Rogers AV, et al. Myofibroblast involvement in the allergen-induced late response in mild atopic asthma Am J Respir Cell Mol Biol 1997; 16:664-673.
48. Canonica GW. Treating asthma as an inflammatory disease. Chest 2006; 130:21S-28S.
49. King GG, Pare PD, Seow CY. The mechanics of exaggerated airway narrowing in asthma: the role of smooth muscle. Respir Physiol 1999; 118:1-13.
50. Porter KE, Turner NA, O'Regan DJ, et al. Simvastatin reduces human atrial myofibroblast proliferation independently of cholesterol lowering via inhibition of RhoA. Cardiovasc Res 2004; 61:745-755.
51. Ikeuchi H, Kuroiwa T, Yamashita S, et al. Fluvastatin reduces renal fibroblast proliferation and production of type III collagen: therapeutic implications for tubulointerstitial fibrosis. Nephron Exp Nephrol 2004; 97:115-122.
52. Watts KL, Sampson EM, Schultz GS, Sprien MA. Simvastatin inhibits growth factor expression and modulates profibrogenic markers in lung fibroblasts. Am J Respir Cell Mol Biol 2005; 32:290-300.
53. Bucca C, Marsico A, Panaro E, et al. Statins and nasal polyps. Ann Intern Med 2005; 142:310-311.
54. Folli C, Descalzi D, Bertolini S, et al. Effect of statins on fibroblasts from human nasal polyps and turbinates. Eur Ann Allergy Clin Immunol (in press).
55. Diamant Z, Boot JD, Virchow JC. Summing up 100 years of asthma. Respir Med 2007; 101:378-388. This review summarizes the history and therapy of asthma in the last 100 years.
56. Capraz F, Kunter E, Cermik H, et al. The effect of inhaled budesonide and formoterol on bronchial remodeling and HRCT features in young asthmatics. Lung 2007; 185:89-96.
57. Bergeron C, Hauber HP, Gotfned M, et al. Evidence of remodeling in peripheral airways of patients with mild to moderate asthma: effect of bydrofluoroalkane-flunisolide. J Allergy Clin Immunol 2005; 116:983-989.
58. Chetta A, Zanmi A, Foresi A, ef al. Vascular component of airway remodeling in asthma is reduced by high dose of fluticasone. Am J Respir Crit Care Med 2003; 167:751-757.
59. Cazes E, Giron-Michel J, Baouz S, et al. Novel anti-inflammatory effects of the inhaled corticosteroid fluticasone propionate during lung myofibroblastic differentiation. J Immunol 2001; 167:5329-5337.
60. Oddera S, Cagnoni F, Mangraviti S, et al. Effects of tnamcinolone acetonide on adult human lung fibroblasts: decrease in proliferation, surface molecule expression and mediator release. Int Arch Allergy Immunol 2002; 129:152-159.
61. Rodrigo GJ. Rapid effects of inhaled corticosteroids in acute asthma: an evidence-based evaluation. Chest 2006; 130:1301-1311.
62. Goulet S, Bihl MP, Gambazzi F, et al. Opposite effect of corticosteroids and long-acting beta(2)-agonists on serum- and TGF-beta(1)-induced extracellular matrix deposition by primary human lung fibroblasts. J Cell Physiol 2007; 210:167-176.
63. Roth M, Johnson P, Riidiger JJ, et al. Interaction between glucocorticoids and β2 agonists on bronchial airway smooth muscle ceils through synchronised cellular signalling. Lancet 2002; 360:1265-1266.
64. Baouz S, Giron-Michel J, Azzarone B, et al. Lung myofibroblasts as targets of salmeterol and fluticasone propionate: inhibition of alpha-SMA and NF-kappaB. Int Immunol 2005; 17:1473-1481.
65. Descalzi D, Folli C, Nicolini G, et al. Antiproliferative and anti remodelling effect of beclomethasone dipropionate, formoterol and salbutamol alone or in combination in primary human bronchial fibroblasts. Allergy 2008; 63:432-437.
66. Eickelberg. Ligand-independent activation of the glucocorticoid receptor by beta2-adrenergic receptor agonists in primary human lung fibroblasts and vascular smooth muscle cells. J Biol Chem 1999; 274:1005-1010.
67. Johnson M. Combination therapy for asthma: complementary effects of longacting beta2-agonists and corticosteroids. Curr Allergy Clin Immunol 2002; 15:16-22.
68. Kom SH, Jerre A, Brattsand R. Effects of formoterol and budesonide on GM-CSF and IL-8 secretion by triggered human bronchial epithelial cells. Eur Respir J 2001; 17:1070-1077.
69. Profita M, Gagliardo R, Di Giorgi R, et al. Biochemical interaction between effects of beclomethasone dipropionate and salbutamol or formoterol in sputum cells from mild to moderate asthmatics. Allergy 2005; 60:323-329.
70. Failla M, Crimi N, Vancheri C. Exhaled bronchial cysteinyl leukotrienes in allergic patients. Curr Opin Allergy Clin Immunol 2007; 7:25-31.
71. Kelly MM, Chakir J, Vethanayagam D, et al. Montelukast treatment attenuates the increase in myofibroblasts following low-dose allergen challenge. Chest 2006; 130:741-753.
72. Henderson WR Jr, Chiang GK, Tien YT, Chi EY. Reversal of allergen-induced airway remodeling by CysLT1 receptor blockade. Am J Respir Crit Care Med 2006; 173:718-728.
73. Tamesis GP, Krawiec ME. Heterogeneity in response to asthma medications. Curr Opin Allergy Clin Immunol 2007; 7:185-189.
74. Lagente V, Martin-Chouly C, Boichot E, et al. Selective PDE4 inhibitors as potent anti-inflammatory drugs for the treatment of airway diseases. Mem Inst Oswaldo Cruz 2005; 100 (S1):131-136.
75. Fan Chung K. Phosphodiesterase inhibitors in airways disease. Eur J Pharmacol 2006; 533:110-117.
76. Lipworth BJ. Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease. Lancet 2005; 365:167-175.
77. Karpel J, Bukstein DA, LoNigro R. The appropriate omalizumab patient. Manag Care 2007; 16:44-50.
78. Nowak D. Management of asthma with antiimmunoglobulin E: a review of clinical trials of omalizumab. Respir Med 2006; 100:1907-1917.
79. Buhl R, Hanf G, Solèr M, et al. The anti-IgE antibody omalizumab improves asthma-related quality of life in patients with allergic asthma. Eur Respir J 2002; 20:1088-1094.
80. Buhl R, Solèr M, Matz J, et al. Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma. Eur Respir J 2002; 20:73-78.
81. Papi A, Canonica GW, Maestrelli P, et al. Rescue use of beclomethasone and albuterol in a single inhaler for mild asthma. N Engl J Med 2007; 356:2040-2052. A 6-month study which demonstrates that in patients with mild asthma the symptom-driven use of inhaled beclomethasone and albuterol in a single inhaler is as effective as the regular use of inhaled beclomethasone.
82. Boushey HA, Sorkness CA, King TS, et al. Daily versus as-needed corticosteroids for mild persistent asthma. N Engl J Med 2005; 352:1519-1528.